CD274 and lung carcinoma: More importantly, we examined the synergistic effect of combining SD70, an epigenetic KDM4C-specific inhibitor, with RT and an anti-PD-L1 antibody and found that among the tested regimens, this triple therapy produced the best antitumor effects with tolerable toxicity in lung cancer.